Latest Hotspot

I-Mab Unveils Promising Phase 1 Results for Ragistomig at ASCO 2024

29 May 2024
3 min read

I-Mab, a global biotechnology firm headquartered in the United States, which specializes in the innovation and potential market launch of distinct immunotherapies designed to treat cancer, revealed that Dr. Gerald Falchook and the I-Mab’s collaborator for ragistomig (also known as "ABL503"), ABL Bio, will showcase a poster featuring Phase 1 data for ragistomig at the 2024 American Society for Clinical Oncology Annual Meeting. This event is scheduled to be held from May 31st to June 4th at the McCormick Place Convention Center in Chicago, Illinois.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

图形用户界面, 文本, 应用程序, 电子邮件, Teams

描述已自动生成

Ragistomig was developed as a bispecific antibody designed to integrate anti-PD-L1 functionality with 4-1BB-driven T-cell activation within a single molecule. The strategy incorporated an Fc-silent and conditional 4-1BB engagement aimed at enhancing safety, particularly by potentially reducing hepatotoxicity when compared to conventional 4-1BB agonists.

"We are excited to present the latest Phase 1 data for ragistomig at ASCO 2024. Although immune checkpoint inhibitors have greatly advanced the treatment of solid tumors, a number of tumors either do not respond or eventually become resistant to these agents. Ragistomig aims to offer a novel therapeutic option for patients who are resistant to immune checkpoint inhibitors," stated Raj Kannan, Chief Executive Officer at I-Mab.

"Initial data suggest that the study has achieved its goals, allowing us to define an optimal dosage and showing early signs of efficacy in patients who have relapsed or are refractory to previous checkpoint inhibitor treatments. These findings further support the ongoing development of ragistomig not only as a monotherapy but also in combination with other treatments. We are eager to progress the clinical program in partnership with ABL Bio," Raj Kannan added.

Jointly developed with ABL Bio, ragistomig (also referred to as ABL503) is a unique bispecific antibody targeting PD-L1. It combines an Fc-silent anti-PD-L1 arm, which acts as the tumor-dependent T-cell activator, with a single chain variable fragment of an anti-4-1BB engaging antibody, serving as the conditional T-cell activator in the presence of tumor engagement.

Leveraging ABL Bio's "Grabody-T" bispecific antibody platform technology, ragistomig/ABL503 specifically activates 4-1BB only when PD-L1 expressing tumor cells are present, thereby minimizing the risk of off-tumor toxicity and addressing resistance to PD-(L)1 inhibition. Preclinical studies have shown that the bispecific antibody exhibits superior anti-tumor activity compared to equimolar doses of single agents, whether used alone or in combination..

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面

中度可信度描述已自动生成

According to the data provided by the Synapse Database, As of May 29, 2024, there are 27 investigational drugs for the 4-1BB x PDL1 targets, including 45 indications, 35 R&D institutions involved, with related clinical trials reaching 75, and as many as 9941 patents.

Ragistomig is a bispecific antibody drug that targets 4-1BB x PDL1 and is primarily focused on the therapeutic areas of neoplasms. Ragistomig represents a promising development in the field of biomedicine, particularly in the area of cancer immunotherapy. As the drug progresses through clinical development, further insights into its potential benefits and limitations will likely emerge, ultimately shaping its future role in the treatment of advanced malignant solid neoplasms.

图形用户界面, 文本, 网站

描述已自动生成

BioAtla to Present Promising Phase 1 Evalstotug Trial Results at 2024 ASCO Conference
Latest Hotspot
3 min read
BioAtla to Present Promising Phase 1 Evalstotug Trial Results at 2024 ASCO Conference
29 May 2024
BioAtla to Showcase Phase 1 Evalstotug Clinical Trial Outcomes Highlighting Clinical Benefits at the 2024 ASCO Annual Conference.
Read →
Sensei Biotherapeutics Shares Encouraging Phase 1 Dose Escalation Study Results for SNS-101
Latest Hotspot
3 min read
Sensei Biotherapeutics Shares Encouraging Phase 1 Dose Escalation Study Results for SNS-101
29 May 2024
Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.
Read →
Coherus Reveals Initial Findings from Phase I Dose-escalation Trial of its CCR8-targeting Antibody, CHS-114
Latest Hotspot
3 min read
Coherus Reveals Initial Findings from Phase I Dose-escalation Trial of its CCR8-targeting Antibody, CHS-114
29 May 2024
Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.
Read →
Cure Genetics Unveils Positive Safety and Efficacy of CAR-NKT Therapy CGC729 in RCC at ASGCT 2024
Latest Hotspot
3 min read
Cure Genetics Unveils Positive Safety and Efficacy of CAR-NKT Therapy CGC729 in RCC at ASGCT 2024
29 May 2024
Cure Genetics Revealed Positive Safety and Effectiveness Data for CAR-NKT Treatment CGC729 in RCC at ASGCT 2024.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.